Reports
Sale
Hepatic Encephalopathy Treatment Market Size, Share, Report: By Drug Class: Antibiotics, Laxatives, L-ornithine, L-aspartate, Others; By Diagnosis: Blood Tests, CT Scan, Liver Functioning Tests (LFT), Others; By Treatment; By Route of Administration; By End User, By Distribution Channels; Regional Analysis; Supplier Landscape; 2024-2032
Hepatic Encephalopathy Treatment Market Outlook
The hepatic encephalopathy treatment market size was valued at USD 1.6 billion in 2023, driven by the rising incidence of liver cirrhosis across the 7 major markets. The market is expected to grow at a CAGR of 5.7% during the forecast period of 2024-2032, with the values likely to rise from USD 1.7 billion in 2024 to USD 2.6 billion by 2032.
Hepatic Encephalopathy Treatment: Introduction
Hepatic encephalopathy is a temporary neurological disorder that occurs due to a severe liver disease. The damaged liver fails to clear out the toxins effectively and toxins build up reaches the brain through the blood stream. It causes cognitive impairment and affects brain function. Hepatic encephalopathy is commonly managed by antibiotics and laxatives. However, the treatment may vary depending upon the symptoms and overall health of the patient.
Hepatic Encephalopathy Treatment Market Analysis
The hepatic encephalopathy treatment market demand is mostly driven by the increasing prevalence of liver-associated diseases which include liver cirrhosis, hepatitis, and fatty liver.
Nonabsorbable disaccharides, such as lactulose or lactitol, are considered as the first in-line treatment for the condition. They function by lowering the absorption of ammonia in the body. Another commonly used treatment method is the use of antibiotics. They are used to alter the gut microbiota to create a more favourable microbiome that leads to decreased endogenous bacterial production of ammonia. Rifaximin, Neomycin and Metronizadole are frequently prescribed to treat the condition.
Dietary treatment alternatives that naturally lower down the ammonia levels in the body can also be applied. Using intravenous L-ornithine-L-aspartate has been proven helpful in lowering the severity of the condition in some patients. If the condition persists due to complete liver damage, then liver transplant is the last alternative recommended by healthcare professionals.
Apart from pharmaceuticals, the hepatic encephalopathy treatment market value is also driven by the rising advancements in diagnostics. Tests like electroencephalography are used to determine the severity of the condition and facilitate effective treatment based on it.
Hepatic Encephalopathy Treatment Market Segmentation
Market Breakup by Drug Class
- Antibiotics
- Laxatives
- L-ornithine
- L-aspartate
- Others
Market Breakup by Diagnosis
- Blood Tests
- CT Scan
- Liver Functioning Tests (LFT)
- Others
Market Breakup by Treatment
- Medication
- Surgery
- Others
Market Breakup by Route of Administration
- Oral
- Injectable
- Intravenous
- Rectal
- Others
Market Breakup by End User
- Hospitals
- Homecare
- Speciality Clinics
- Others
Market Breakup by Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Hepatic Encephalopathy Treatment Market Overview
The United States has been proactive in mitigating the rising burden of liver diseases. The region has held a substantial percentage of the hepatic encephalopathy treatment market share. With increasing drug development and other treatment alternatives, there has been significant emphasis on educating the population on identifying the early stages of liver damage. This has been made possible through awareness campaigns and initiatives set up by government as well as private institutions. In July 2023, the World Health Organization launched “One Life, One Liver” campaign, aimed at protecting liver health.
Alcohol consumption, obesity and sedentary lifestyle are major factors contributing to liver diseases. Hence, Europe is also a significant player of the hepatic encephalopathy treatment market. With well-equipped medical infrastructure and staff, it can pioneer the treatment market by bringing groundbreaking innovations to improve the efficacy of medicines.
With a high percentage of geriatric population, the Asia Pacific region is expected to witness rapid hepatic encephalopathy treatment market growth in the coming years. The region has been experiencing major mergers and acquisitions among impactful companies, which are anticipated to fuel market growth. With an influx of foreign investments, the medical infrastructure is also improving.
Hepatic Encephalopathy Treatment Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Salix Pharmaceuticals
- Mallinckrodt plc.
- Merck & Co., Inc.
- Bausch Health
- Takeda Pharmaceutical Company Limited
- Johnson & Johnson Services, Inc.
- Eisai Co., Ltd
- AbbVie Inc.
- Hikma Pharmaceuticals PLC
- Vedanta Biosciences
- Patricia Bloom
- Umecrine Cognition
- Axcella Health Inc.
- Pfizer Inc.
- Rebiotix
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Diagnosis |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Hepatic Encephalopathy Treatment Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Hepatic Encephalopathy Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.3.1 Germany Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.3.2 France Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.3.3 Italy Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.3.4 Spain Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
5.4 Japan Hepatic Encephalopathy Epidemiology Forecast (2017-2032)
6 Hepatic Encephalopathy Treatment Market Overview – 7MM
6.1 Hepatic Encephalopathy Treatment Market Historical Value (2017-2023)
6.2 Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032)
7 Hepatic Encephalopathy Treatment Market Landscape – 7MM
7.1 Amyotrophic Lateral Sclerosis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Hepatic Encephalopathy Treatment Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Treatment
7.2.3 Analysis by Route of Administration
8 Hepatic Encephalopathy Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Hepatic Encephalopathy Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Hepatic Encephalopathy Treatment Market Segmentation – 7MM
11.1 Hepatic Encephalopathy Treatment Market by Drug Class
11.1.1 Market Overview
11.1.2 Antibiotics
11.1.3 Laxatives
11.1.4 L-ornithine
11.1.5 L-aspartate
11.1.6 Others
11.2 Hepatic Encephalopathy Treatment Market by Diagnosis
11.2.1 Market Overview
11.2.2 Blood Tests
11.2.3 CT Scan
11.2.4 Liver Functioning Tests (LFT)
11.2.5 Others
11.3 Hepatic Encephalopathy Treatment Market by Treatment
11.3.1 Market Overview
11.3.2 Medication
11.3.3 Surgery
11.3.4 Others
11.4 Hepatic Encephalopathy Treatment Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Injectable
11.4.4 Intravenous
11.4.5 Rectal
11.4.6 Others
11.5 Hepatic Encephalopathy Treatment Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Homecare
11.5.4 Speciality Clinics
11.5.5 Others
11.6 Hepatic Encephalopathy Treatment Market by Distribution Channels
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
11.6.5 Others
11.7 Hepatic Encephalopathy Treatment Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
12 United States Hepatic Encephalopathy Treatment Market
12.1 Hepatic Encephalopathy Treatment Market Historical Value (2017-2023)
12.2 Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032)
12.3 Hepatic Encephalopathy Treatment Market by Drug Class
12.4 Hepatic Encephalopathy Treatment Market by Treatment
13 EU-4 and United Kingdom Hepatic Encephalopathy Treatment Market
13.1 Hepatic Encephalopathy Treatment Market Historical Value (2017-2023)
13.2 Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032)
13.3 Germany Hepatic Encephalopathy Treatment Market Overview
13.3.1 Hepatic Encephalopathy Treatment Market by Drug Class
13.3.2 Hepatic Encephalopathy Treatment Market by Treatment
13.4 France Hepatic Encephalopathy Treatment Market Overview
13.4.1 Hepatic Encephalopathy Treatment Market by Drug Class
13.4.2 Hepatic Encephalopathy Treatment Market by Treatment
13.5 Italy Hepatic Encephalopathy Treatment Market Overview
13.5.1 Hepatic Encephalopathy Treatment Market by Drug Class
13.5.2 Hepatic Encephalopathy Treatment Market by Treatment
13.6 Spain Hepatic Encephalopathy Treatment Market Overview
13.6.1 Hepatic Encephalopathy Treatment Market by Drug Class
13.6.2 Hepatic Encephalopathy Treatment Market by Treatment
13.7 United Kingdom Hepatic Encephalopathy Treatment Market Overview
13.7.1 Hepatic Encephalopathy Treatment Market by Drug Class
13.7.2 Hepatic Encephalopathy Treatment Market by Treatment
14 Japan Hepatic Encephalopathy Treatment Market
14.1 Hepatic Encephalopathy Treatment Market Historical Value (2017-2023)
14.2 Hepatic Encephalopathy Treatment Market Forecast Value (2024-2032)
14.3 Hepatic Encephalopathy Treatment Market by Drug Class
14.4 Hepatic Encephalopathy Treatment Market by Treatment
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Salix Pharmaceuticals
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Mallinckrodt plc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Merck & Co., Inc.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Bausch Health
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Takeda Pharmaceutical Company Limited
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Johnson & Johnson Services, Inc.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Eisai Co., Ltd
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 AbbVie Inc.
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Hikma Pharmaceuticals PLC
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Vedanta Biosciences
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Patricia Bloom
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Umecrine Cognition
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Axcella Health Inc.
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifictions
21.14 Pfizer Inc.
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Rebiotix
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Hepatic Encephalopathy Treatment Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 1.6 billion in 2023, driven by rising incidence of liver cirrhosis.
The market is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032, likely to reach a market value of USD 2.6 billion by 2032.
The market demand is driven by increasing burden of liver diseases and increasing alcohol consumption around the 7 major markets.
The key trends which are bolstering the market growth include the increasing focus on combination therapies and increasing drug approvals for treating hepatic encephalopathy.
The drug classes in the market include antibiotics, laxatives, L-ornithine, and L-aspartate, among others.
The treatments in the market are blood tests, CT scan, and liver functioning tests (LFT), among others.
The different routes of administration are oral, injectable, intravenous, and rectal, among others.
The end-users in the market are hospitals, homecare, and specialty clinics, among others.
The distribution channels available in the market are hospital pharmacy, retail pharmacy, and online pharmacy, among others.
The major regions of the market include the United States, Japan, EU-4 and the United Kingdom. EU-4 comprises of Germany, France, Italy, and Spain.
Key players involved in the market are Salix Pharmaceuticals, Mallinckrodt plc., Merck & Co., Inc., Bausch Health, Takeda Pharmaceutical Company Limited, Johnson & Johnson Services, Inc., Eisai Co., Ltd, AbbVie Inc., Hikma Pharmaceuticals PLC, Vedanta Biosciences, Patricia Bloom, Umecrine Cognition, Axcella Health Inc., Pfizer Inc., and Rebiotix.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER